AtomVie Global Radiopharma Partners with Ionetix Corporation for Ac-225 Supply Agreement to Enhance Radiotherapy Development
In a significant advancement for the radiopharmaceutical sector, AtomVie Global Radiopharma has announced a strategic partnership with Ionetix Corporation aimed at enhancing the availability of clinical-grade Actinium-225 (Ac-225). This partnership is set against the backdrop of rising demand for effective radiotherapies based on alpha particles and puts AtomVie in a strong position as they prepare for the commissioning of their state-of-the-art manufacturing facility. Actinium-225, an alpha-emitting radioisotope, is pivotal in the development of next-generation targeted radiopharmaceuticals. The focus on Ac-225 systematizes AtomVie’s commitment to providing a reliable supply of medical isotopes, which are essential for facilitating various treatment programs, from research stages to clinical applications.
According to Bruno Paquin, CEO of AtomVie, having consistent access to high-quality radioisotopes like Ac-225 is crucial for the evolution of targeted radiotherapy options. "Our collaboration with Ionetix strengthens our ability to support clients developing innovative alpha therapies while ensuring a secure clinical supply chain," said Paquin. With Ionetix supplying the Ac-225 that adheres to Good Manufacturing Practices (GMP), customers will now be able to execute their programs smoothly.
The agreement promises not only to broaden the service offerings that AtomVie can extend to its clients but also affirms its dedication to addressing the growing needs in the field of alpha therapy innovations. As AtomVie gears up to open its new facility, the partnership with Ionetix represents a strategic move to align supply capabilities directly within their bespoke development and manufacturing services.
Ionetix Corporation, recognized for its leading role in cyclotron technology and radioisotope production, will provide high-purity Ac-225 in a specialized operational network that facilitates ease of access globally. David Eve, Vice President of Medical Affairs at Ionetix, emphasized how this partnership enhances the reliability and scalability of therapeutic developments. He remarked, "By supplying Ac-225 for clinical use, we are making the pathway more dependable for companies aiming to bring promising alpha therapies to patients."
The collaboration aims to actively support the innovations in radiopharmacology, meeting the increasing demands for impactful alpha therapy development. With their combined expertise, AtomVie and Ionetix are well-positioned to pioneer advancements in the distribution of targeted therapies across various global markets.
AtomVie stands as a premier contract development and manufacturing organization focused on the global distribution of clinical and commercial radiopharmaceutical products. It provides a comprehensive array of scientific, technical, regulatory, quality, and logistical services tailored to the needs of their clients. Currently engaged with international partners, AtomVie will soon launch a new 72,300 square foot facility designed to provide cutting-edge radiopharmaceutical production capabilities. With the operational launch expected in the first quarter of 2026, both companies anticipate strengthening their competitive edge in an evolving medical landscape. More information about their services and the partnership can be found on AtomVie’s website.
This partnership marks a significant step towards accelerating the progression of radiopharmaceutical technologies. As AtomVie and Ionetix continue to enhance their operational synergies, the prospect of delivering potent and refined therapies becomes even more viable, promising a bright future for patients who depend on these crucial treatments.
According to Bruno Paquin, CEO of AtomVie, having consistent access to high-quality radioisotopes like Ac-225 is crucial for the evolution of targeted radiotherapy options. "Our collaboration with Ionetix strengthens our ability to support clients developing innovative alpha therapies while ensuring a secure clinical supply chain," said Paquin. With Ionetix supplying the Ac-225 that adheres to Good Manufacturing Practices (GMP), customers will now be able to execute their programs smoothly.
The agreement promises not only to broaden the service offerings that AtomVie can extend to its clients but also affirms its dedication to addressing the growing needs in the field of alpha therapy innovations. As AtomVie gears up to open its new facility, the partnership with Ionetix represents a strategic move to align supply capabilities directly within their bespoke development and manufacturing services.
Ionetix Corporation, recognized for its leading role in cyclotron technology and radioisotope production, will provide high-purity Ac-225 in a specialized operational network that facilitates ease of access globally. David Eve, Vice President of Medical Affairs at Ionetix, emphasized how this partnership enhances the reliability and scalability of therapeutic developments. He remarked, "By supplying Ac-225 for clinical use, we are making the pathway more dependable for companies aiming to bring promising alpha therapies to patients."
The collaboration aims to actively support the innovations in radiopharmacology, meeting the increasing demands for impactful alpha therapy development. With their combined expertise, AtomVie and Ionetix are well-positioned to pioneer advancements in the distribution of targeted therapies across various global markets.
AtomVie stands as a premier contract development and manufacturing organization focused on the global distribution of clinical and commercial radiopharmaceutical products. It provides a comprehensive array of scientific, technical, regulatory, quality, and logistical services tailored to the needs of their clients. Currently engaged with international partners, AtomVie will soon launch a new 72,300 square foot facility designed to provide cutting-edge radiopharmaceutical production capabilities. With the operational launch expected in the first quarter of 2026, both companies anticipate strengthening their competitive edge in an evolving medical landscape. More information about their services and the partnership can be found on AtomVie’s website.
This partnership marks a significant step towards accelerating the progression of radiopharmaceutical technologies. As AtomVie and Ionetix continue to enhance their operational synergies, the prospect of delivering potent and refined therapies becomes even more viable, promising a bright future for patients who depend on these crucial treatments.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.